Daiichi Sankyo Co.

Daiichi Sankyo Company, Limited

Type	Public KK
Traded as	: TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component NASDAQ: DSNKY
Industry	Pharmaceutical
Predecessor	Daiichi Pharmaceutical Company Sankyo Company
Founded	Tokyo, Japan (2005) (by merger)
Headquarters	Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan
Key people	Joji Nakayama, (CEO and President)
Products	Medical equipment Pharmaceutical products Veterinary medicines
Revenue	$ 12.006 billion USD (FY 2012) (¥ 997.852 billion JPY) (FY 2012)
Net income	$ 0.801 billion USD (FY 2012) (¥ 66.621 billion JPY) (FY 2012)
Number of employees	32,229 (as of December 2013)
Website	http://www.daiichisankyo.com
Footnotes / references

$ 12.006 billion USD (FY 2012)

$ 0.801 billion USD (FY 2012)

Daiichi Sankyo Company, Limited (第一三共株式会社, Daiichi Sankyō Kabushiki-kaisha^?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Parsippany, New Jersey.